Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research

Journal of Pharmacological and Toxicological Methods

Volumn 64, Issue 3, 2011, Pages 197-206

  Bateson, Hannah ^a   Saleem, Saira ^a   Loadman, Paul M ^a   Sutton, Chris W ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Biomarker; Cancer; MALDI; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

ANALYTIC METHOD; BLOOD SAMPLING; CANCER RESEARCH; FUNCTIONAL PROTEOMICS; HUMAN; INTERMETHOD COMPARISON; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; PROTEIN ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; STRUCTURAL PROTEOMICS;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 81955168096     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.04.003     Document Type: Review

References (65)

1. Alexander H., Stegner A.L., Wagner-Mann C., Du Bois G.C., Alexander S., Sauter E.R. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clinical Cancer Research 2004, 10:7500-7510.
2. Atkinson S.J., Loadman P.M., Sutton C., Patterson L.H., Clench M.R. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Communications in Mass Spectrometry 2007, 21:1271-1276.
3. Baak J.P., Janssen E.A., Soreide K., Heikkilae R. Genomics and proteomics-The way forward. Annals of Oncology 2005, 16(Suppl 2):ii30-ii44.
4. Beavis R.C., Chait B.T. Cinnamic acid derivatives as matrices for ultraviolet laser desorption mass spectrometry of proteins. Rapid Communications in Mass Spectrometry 1989, 3:432-435.
5. Burger D., Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: The missing link between infection and chronic inflammation?. Autoimmunity Reviews 2002, 1:111-117.
6. Callesen A.K., Vach W., Jorgensen P.E., Cold S., Mogensen O., Kruse T.A., et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: A systematic review. Journal of Proteome Research 2008, 7:1395-1402.
7. Calvano C.D., Aresta A., Iacovone M., De Benedetto G.E., Zambonin C.G., Battaglia M., et al. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles. Journal of Pharmaceutical and Biomedical Analysis 2010, 51:907-914.
8. Celis J.E., Gromov P., Cabezon T., Moreira J.M., Ambartsumian N., Sandelin K., et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: A novel resource for biomarker and therapeutic target discovery. Molecular & Cellular Proteomics 2004, 3:327-344.
9. Chaurand P., Schwartz S.A., Billheimer D., Xu B.J., Crecelius A., Caprioli R.M. Integrating histology and imaging mass spectrometry. Analytical Chemistry 2004, 76:1145-1155.
10. Dai S., Wang X., Liu L., Liu J., Wu S., Huang L., et al. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Science in China Series C, Life Sciences 2007, 50:305-311.
11. Deng S.S., Xing T.Y., Zhou H.Y., Xiong R.H., Lu Y.G., Wen B., et al. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genomics, Proteomics & Bioinformatics 2006, 4:165-172.
12. Djidja M.C., Francese S., Loadman P.M., Sutton C.W., Scriven P., Claude E., et al. Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections. Proteomics 2009, 9:2750-2763.
13. Drake R.R., White K.Y., Fuller T.W., Igwe E., Clements M.A., Nyalwidhe J.O., Given R.W., Lance R.S., Semmes O.J. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. Journal of Proteomics 2009, 72:907-917.
14. Ehmann M., Felix K., Hartmann D., Schnolzer M., Nees M., Vorderwulbecke S., et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34:205-214.
15. Engwegen J.Y., Helgason H.H., Cats A., Harris N., Bonfrer J.M., Schellens J.H., et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World Journal of Gastroenterology 2006, 12:1536-1544.
16. Escher N., Kaatz M., Melle C., Hipler C., Ziemer M., Driesch D., et al. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia (New York, N.Y.) 2007, 9:254-259.
17. Fenn J.B., Mann M., Meng C.K., Wong S.F., Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246:64-71.
18. Fung E.T., Yip T.T., Lomas L., Wang Z., Yip C., Meng X.Y., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. International Journal of Cancer 2005, 115:783-789.
19. Goldman R., Ressom H.W., Abdel-Hamid M., Goldman L., Wang A., Varghese R.S., et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis 2007, 28:2149-2153.
20. Gomme P.T., McCann K.B., Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discovery Today 2005, 10:267-273.
21. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biology 2003, 4:117.
22. Griffin T.J., Gygi S.P., Rist B., Aebersold R., Loboda A., Jilkine A., et al. Quantitative proteomic analysis using a MALDI quadrupole time-of-flight mass spectrometer. Analytical Chemistry 2001, 73:978-986.
23. Groseclose M.R., Massion P.P., Chaurand P., Caprioli R.M. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008, 8:3715-3724.
24. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology 1999, 17:994-999.
25. Hall A.K. Differential expression of thymosin genes in human tumors and in the developing human kidney. International Journal of Cancer 1991, 48:672-677.
26. Hoffman M.D., Sniatynski M.J., Kast J. Current approaches for global post-translational modification discovery and mass spectrometric analysis. Analytica Chimica Acta 2008, 627:50-61.
27. Jurinke C., van den Boom D., Jacob A., Tang K., Worl R., Koster H. Analysis of ligase chain reaction products via matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry. Analytical Biochemistry 1996, 237:174-181.
28. Karas M., Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Analytical Chemistry 1988, 60:2299-2301.
29. Karpova, M. A., Moshkovskii, S. A., Toropygin, I. Y., & Archakov, A. I. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics, 73, 537-551.
30. Kim D.H., Bae J., Lee J.W., Kim S.Y., Kim Y.H., Bae J.Y., et al. Proteomic analysis of breast cancer tissue reveals upregulation of actin-remodeling proteins and its relevance to cancer invasiveness. Proteomics. Clinical Applications 2009, 3:30-40.
31. Koomen J.M., Shih L.N., Coombes K.R., Li D., Xiao L.C., Fidler I.J., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clinical Cancer Research 2005, 11:1110-1118.
32. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-4596.
33. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin E.F., Liotta L.A., et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clinical Chemistry 2007, 53:1067-1074.
34. Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.L., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clinical Cancer Research 2005, 11:1073-1085.
35. Miguet L., Bogumil R., Decloquement P., Herbrecht R., Potier N., Mauvieux L., et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. Journal of Proteome Research 2006, 5:2258-2269.
36. Moshkovskii S.A., Serebryakova M.V., Kuteykin-Teplyakov K.B., Tikhonova O.V., Goufman E.I., Zgoda V.G., et al. Ovarian cancer marker of 11.7kDa detected by proteomics is a serum amyloid A1. Proteomics 2005, 5:3790-3797.
37. Nonami H., Tanaka K., Fukuyama Y., Erra-Balsells R. beta-Carboline alkaloids as matrices for UV-matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in positive and negative ion modes. Analysis of proteins of high molecular mass, and of cyclic and acyclic oligosaccharides. Rapid Communications in Mass Spectrometry 1998, 12:285-296.
38. Office for National Statistics Cancer incidence and mortality 2005-07. Statistical Bulletin. In. 2010.
39. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular & Cellular Proteomics 2002, 1:376-386.
40. Oppenheimer S.R., Mi D., Sanders M.E., Caprioli R.M. Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. Journal of Proteome Research 2010, 9:2182-2190.
41. Overall C.M., Blobel C.P. In search of partners: linking extracellular proteases to substrates. Nature Reviews Molecular Cell Biology 2007, 8:245-257.
42. Overall C.M., Dean R.A. Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Reviews 2006, 25:69-75.
43. Owen C.A., Campbell E.J. The cell biology of leukocyte-mediated proteolysis. Journal of Leukocyte Biology 1999, 65:137-150.
44. Pieles U., Zurcher W., Schar M., Moser H.E. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. Nucleic Acids Research 1993, 21:3191-3196.
45. Pucci-Minafra I., Cancemi P., Albanese N.N., Di Cara G., Marabeti M.R., Marrazzo A., et al. New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator. Journal of Proteome Research 2008, 7:1412-1418.
46. Pucci-Minafra I., Cancemi P., Fontana S., Minafra L., Feo S., Becchi M., et al. Expanding the protein catalogue in the proteome reference map of human breast cancer cells. Proteomics 2006, 6:2609-2625.
47. Puglisi C., Samperi F., Carroccio S., Montaudo G. Analysis of poly(bisphenol A carbonate) by size exclusion chromatography/matrix-assisted laser desorption/ionization. 1. End group and molar mass determination. Rapid Communications in Mass Spectrometry 1999, 13:2260-2267.
48. Rauser, S., Marquardt, C., Balluff, B., Deininger, S. O., Albers, C., Belau, E., Hartmer, R., Suckau, D., Specht, K., Ebert, M. P., Schmitt, M., Aubele, M., Hofler, H., & Walch, A. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res, 9, 1854-1863.
49. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular & Cellular Proteomics 2004, 3:1154-1169.
50. Skipworth R.J., Stewart G.D., Bhana M., Christie J., Sturgeon C.M., Guttridge D.C., et al. Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. International Journal of Oncology 2010, 36:973-982.
51. Song J., Patel M., Rosenzweig C.N., Chan-Li Y., Sokoll L.J., Fung E.T., et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clinical Chemistry 2006, 52:1045-1053.
52. Stoeckli M., Chaurand P., Hallahan D.E., Caprioli R.M. Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nature Medicine 2001, 7:493-496.
53. Sutton C.W., Rustogi N., Gurkan C., Scally A., Loizidou M.A., Hadjisavvas A., et al. Quantitative proteomic profiling of matched normal and tumor breast tissues. Journal of Proteome Research 2010, 9:3891-3902.
54. Tao W.A., Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Current Opinion in Biotechnology 2003, 14:110-118.
55. Tolson J., Bogumil R., Brunst E., Beck H., Elsner R., Humeny A., et al. Serum protein profiling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid alpha in renal cancer patients. Laboratory Investigation 2004, 84:845-856.
56. Umar A., Dalebout J.C., Timmermans A.M., Foekens J.A., Luider T.M. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics 2005, 5:2680-2688.
57. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Molecular & Cellular Proteomics 2006, 5:1840-1852.
58. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. The Journal of Clinical Investigation 2006, 116:271-284.
59. Vostrejs M., Moran P.L., Seligman P.A. Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation. The Journal of Clinical Investigation 1988, 82:331-339.
60. Ward D.G., Suggett N., Cheng Y., Wei W., Johnson H., Billingham L.J., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer 2006, 94:1898-1905.
61. White K.Y., Rodemich L., Nyalwidhe J.O., Comunale M.A., Clements M.A., Lance R.S., et al. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. Journal of Proteome Research 2009, 8:620-630.
62. Yildiz P.B., Shyr Y., Rahman J.S., Wardwell N.R., Zimmerman L.J., Shakhtour B., et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. Journal of Thoracic Oncology 2007, 2:893-901.
63. Zhang Z., Bast R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 2004, 64:5882-5890.
64. Zhang W., Czernik A.J., Yungwirth T., Aebersold R., Chait B.T. Matrix-assisted laser desorption mass spectrometric peptide mapping of proteins separated by two-dimensional gel electrophoresis: Determination of phosphorylation in synapsin I. Protein Science 1994, 3:677-686.
65. Zinkin N.T., Grall F., Bhaskar K., Otu H.H., Spentzos D., Kalmowitz B., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clinical Cancer Research 2008, 14:470-477.